---
layout: default
title: Cangrelor
parent: Nur Modellvorhersage (L5)
nav_order: 84
evidence_level: L5
indication_count: 0
---

# Cangrelor
{: .fs-9 }

Evidenzniveau: **L5** | Vorhergesagte Indikationen: **0** 
{: .fs-6 .fw-300 }

---

## Inhaltsverzeichnis
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmazeutischer Bewertungsbericht

</div>

# Cangrelor: Evidence Pack Incomplete — Full Evaluation Pending

## One-Sentence Summary

Cangrelor (DB06441) is an intravenous P2Y12 receptor antagonist antiplatelet agent, currently not marketed in the evaluated region.
The TxGNN pipeline has **not yet generated any predicted new indications** for this drug in the current data cycle,
meaning no comparative efficacy analysis or evidence review can be conducted at this stage.
This report documents the current data status and outlines the steps required before a formal repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet available |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

No TxGNN predicted indications are present in the current Evidence Pack (`predicted_indications: []`). As a result, there is no repurposing hypothesis to evaluate at this time.

Cangrelor is a direct-acting, reversible intravenous P2Y12 receptor antagonist. It inhibits ADP-induced platelet activation and aggregation by binding to the P2Y12 receptor, and is primarily used in the context of percutaneous coronary intervention (PCI) to reduce periprocedural thrombotic events. However, because the Evidence Pack records `original_moa` as unavailable and `original_indications` as an empty list, these details cannot be formally cited from structured data at this time.

Until the TxGNN scoring pipeline produces a ranked indication list for DB06441, the mechanistic rationale for any specific new indication cannot be assessed. Once predictions are available, the relationship between platelet biology and candidate diseases (e.g., inflammatory, ischaemic, or oncology-adjacent conditions) can be evaluated.

---

## Market Information

No marketing authorizations are on record in the current database for Cangrelor. The drug has market status: **Not marketed** in the evaluated jurisdiction, with zero registered licenses.

---

## Safety Considerations

Please refer to the package insert for safety information. No structured safety data (warnings, contraindications, or drug–drug interactions) was returned in the current Evidence Pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Cangrelor is critically incomplete — no TxGNN predictions, no original indication data, no MOA, and no safety records are available. A formal repurposing evaluation cannot be conducted until these gaps are resolved.

**To proceed, the following is needed:**

- **Re-run TxGNN scoring** for DB06441 to generate a ranked predicted indication list; the current `predicted_indications` array is empty, which may indicate a pipeline execution gap or that the drug was filtered before scoring.
- **Retrieve MOA from DrugBank API** (remediation flagged as DG002, High severity) to enable mechanistic relevance analysis.
- **Download and parse the package insert PDF** from the relevant regulatory authority (remediation flagged as DG001, Blocking severity) to populate warnings and contraindications before any safety screening (S1 gate) can begin.
- **Confirm jurisdiction scope**: The Evidence Pack field is labelled `taiwan_regulatory` but the market status value (`Not marketed`) is in Traditional Chinese — clarify whether this evaluation targets Taiwan, Germany (BfArM), or both, to ensure the correct licence database is queried.
- Once predictions are available, re-generate this report to include clinical trial evidence, literature evidence, and a full safety assessment.
## Haftungsausschluss

Diese Inhalte dienen ausschließlich Forschungszwecken und stellen keine medizinische Beratung dar.
Vor jeder klinischen Anwendung ist eine klinische Validierung erforderlich.

---

